Secukinumab
Indication
Secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (NICE TA445)
NICE TA445 - Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Red
Brand:
Cosentyx ®
Nice TA:
445
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Musculoskeletal system
Background
Secukinumab alone, or in combination with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults only if:
it is used as described in the NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (recommendations 1.1 and 1.2) or
the person has had a TNF-alpha inhibitor but their disease has not responded within the first 12 weeks or has stopped responding after 12 weeks or
TNF-alpha inhibitors are contraindicated but would otherwise be considered (as described in NICE technology appraisal guidance on etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis).
Secukinumab is only recommended if the company provides it as agreed in the patient access scheme.
Response to secukinumab should be assessed after 16 weeks of treatment. Treatment should only be continued if there is clear evidence of response (as define by NICE TA 445).
Recommendation
LSCMMG Recommendation:
Red
Reason for decision:
Specialist medicine
Supporting documents: